Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children
| Autor: | Donald Wells, Priya Mahajan, Jay Poston, Ebrahim S Delpassand, Victor J. Seghers, Jennifer Foster, Rajkumar Venkatramani, Andrew C. Sher, Samara L. Potter |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Receptors Peptide Peptide receptor Disease Neuroendocrine tumors 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Child Radionuclide Imaging Radioisotopes business.industry Midgut Hematology medicine.disease Disease control Clinical trial Neuroendocrine Tumors medicine.anatomical_structure Positron-Emission Tomography 030220 oncology & carcinogenesis Pediatrics Perinatology and Child Health Radionuclide therapy Radiopharmaceuticals Pancreas business 030215 immunology |
| Zdroj: | Pediatric Blood & Cancer. 68 |
| ISSN: | 1545-5017 1545-5009 |
| DOI: | 10.1002/pbc.29056 |
| Popis: | Neuroendocrine tumors (NETs) of the pancreas and midgut are extremely rare in children, and patients presenting with metastatic disease have poor survival. Given this rarity, treatments are extrapolated from guidelines for adults with NET. Recent clinical trials in adults with NETs have shown that the addition of peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE resulted in a disease control rate of nearly 80%, with minimal side effects. We report our experience using 177 Lu-DOTATATE to treat two pediatric patients with metastatic NET. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text